ABSI
NASDAQ HealthcareAbsci Corporation - Common Stock
Biotechnology
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
๐ Market Data
| Price | $8.23 |
|---|---|
| Volume | 7,411,240 |
| Market Cap | 1.39B |
| Beta | 2.330 |
| RSI (14-Day) | 34.9 |
| 200-Day MA | $4.41 |
| 50-Day MA | $7.60 |
| 52-Week High | $12.05 |
| 52-Week Low | $2.24 |
| Forward P/E | -13.22 |
| Price / Book | 7.43 |
๐ฏ Investment Strategy Scores
ABSI scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (96/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ABSI in your text
Paste any article, transcript, or post โ the tool will extract ABSI and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.